Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
You may also be interested in...
Biogen’s potential game-changing multiple sclerosis drug anti-LINGO-1 failed to meet the primary or secondary endpoints of a Phase II study, highlighting the challenges the biotech faces developing treatments for serious CNS disorders.
Celgene pays Agios $200m up front for collaboration in immuno-oncology. Biogen inks pacts with Regenxbio and Penn to apply AAV technology to its developing gene-therapy program.
Biotech gets AAV technology license from Regenx for use in developing therapeutics for rare genetic eye disorders, which will be developed in tandem with University of Pennsylvania researchers.